Objective. To investigate transforming growth factor ␤ (TGF␤) regulation of CCN3 expression in cells of the nucleus pulposus.
The intervertebral disc is a unique structure that permits rotation as well as flexion and extension of the human spine. It is comprised of a gel-like nucleus pulposus surrounded circumferentially by a ligamentous anulus fibrosus. Although cells comprise only ϳ1% of the tissue volume, they are critically important in maintaining a healthy disc (1) . Nucleus pulposus cells secrete and organize a complex extracellular matrix that mainly contains the proteoglycan aggrecan and a small proportion of fibrillar collagens. This macromolecular assembly provides a robust hydrodynamic system that accommodates applied biomechanical forces to the spine (2-4). During degenerative disc disease, loss of disc cells, limited proteoglycan synthesis, and a shift toward synthesis of a fibrotic matrix decrease the water-binding capacity of the disc and result in a failure of the tissue to resist compressive loads (5) .
Growth factors, in particular transforming growth factor ␤ (TGF␤), are known to up-regulate aggrecan synthesis in the disc, and there is evidence that this molecule influences the activities of members of the CCN family of proteins (6, 7) . CCN proteins signal through heparan sulfate proteoglycans and integrins, interacting with, and regulating, the activity of many growth factors. They play important roles in such processes as cell differentiation, proliferation, extracellular matrix synthesis, and angiogenesis (8) (9) (10) (11) (12) . The antiproliferative activities of CCN3 have been documented using embryonic fibroblasts, gliomal cells, vascular smooth muscle cells, and osteogenic mesenchymal cells (13) (14) (15) (16) ; this activity is most likely mediated through association with, and enhancement of, the activities of Notch-1 and connexin 43 (15) (16) (17) . In skeletal tissues, expression of a mutant, truncated CCN3 protein lacking the von Willebrand factor C domain results in enlarged axial and appendicular skeletal elements, increased bone mineralization, severe joint malformations, and disrupted growth plate organization (18) . In epiphyseal chondrocytes, CCN3 is up-regulated early during differentiation, and treatment with the recombinant CCN3 protein causes enhanced expression of type X collagen, suggesting a requirement for CCN3 during the chondrocyte maturation process (19) . Other than a single report that indicates CCN3 expression during early development of the notochord, the anlage of the nucleus pulposus (16) , little is known about the regulation of CCN3 expression and function in the developing intervertebral disc.
The main goal of this investigation was to examine the expression and regulation of CCN3 in cells of the nucleus pulposus and to determine if CCN3 expression is regulated by TGF␤. Results of this study showed that TGF␤ suppressed CCN3 gene expression in a Smad-and activator protein 1 (AP-1)-independent manner; importantly, Smad3 exerted an opposite effect on CCN3 expression. A second goal was to examine the effects of CCN3 on proliferation and on the expression of extracellular matrix components of nucleus pulposus tissue. The studies suggested that during the pathogenesis of degenerative disc disease, the interaction between TGF␤ and members of the CCN family of proteins may provide a reparative function.
MATERIALS AND METHODS
Plasmids and reagents. The human CCN3 reporter plasmid (amino acids -1257 to ϩ317) was from Kurt Engeland (Universitat Leipzig, Leipzig, Germany). Plasmid Smad2 was kindly provided by Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD), TAM67 by Nancy Colburn (National Institutes of Health [NIH] , Bethesda, MD), DN-AP-1 and A-Fos by Charles Vinson (NIH, Bethesda, MD), AP-1 reporter plasmid by Silvio Gutkind (NIH, Bethesda, MD), psiLv-H1-EGFP, pLVTHM-ShSmad3, and pLVTHM by David Danielpour (Case Western Reserve University, Cleveland, OH), DN-p38 plasmids p38␣AF, p38␤2AF, p38␥AF, and p38␦AF by Jiahui Han (Scripps Research Institute, La Jolla, CA), and DN-ERK-1 (ERK-1K71R) and DN-ERK-2 (ERK-2K52R) by Melanie Cobb (University of Texas Southwestern Medical Center, Dallas, TX). Expression plasmids for Smad3 (ID no. 11742), DN-ALK-5 (ID no. 14834), CA-ALK-5 (ID no. 14833), lentiviral packaging psPAX-2 (ID no. 12260), and pMD2.G (ID no. 12259) were obtained from Addgene. As an internal transfection control, vector pGL4.10 (Promega) containing Renilla reniformis luciferase gene was used.
The amount of transfected plasmid, the pretransfection period after seeding, and the posttransfection period before harvesting were optimized for rat nucleus pulposus cells using pSV ␤-galactosidase plasmid (Promega) (20) . Smad3-null mouse embryonic fibroblasts were provided by Dr. Rik Derynck (University of California, San Francisco, San Francisco, CA). Anti-CCN3 rabbit polyclonal K19M antibody was used for CCN3 detection (21) . Recombinant human TGF␤3 and CCN3 were purchased from R&D Systems.
Isolation of nucleus pulposus cells and treatments of cells. Rat nucleus pulposus and anulus fibrosus cells were isolated using a previously reported method (20) . Nucleus pulposus cells and mouse embryonic fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) and 10% fetal bovine serum (FBS) supplemented with antibiotics. In some experiments, cells were treated with recombinant human TGF␤3 (10 ng/ml), recombinant CCN3 (50-500 ng/ml), or recombinant CCN2 (100 ng/ml), all from R&D Systems.
Immunohistologic studies. Freshly isolated rat and mouse spines or whole embryos were immediately fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) and then embedded in paraffin. Transverse and coronal sections, 6-8 m in thickness, were deparaffinized in xylene, rehydrated through graded ethanol, and stained with Alcian blue and with hematoxylin and eosin. For localizing CCN3, sections were incubated with the anti-CCN3 antibody (K19M) in 2% bovine serum albumin in PBS at a dilution of 1:100 at 4°C overnight. After thoroughly washing the sections, the bound primary antibody was incubated for 45 minutes at room temperature with Alexa Fluor 488-conjugated anti-rabbit secondary antibody (Invitrogen), at a dilution of 1:200. Sections were visualized using a fluorescence microscope (Olympus).
Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis. Total RNA was extracted from nucleus pulposus cells using RNeasy Mini Columns (Qiagen). Before elution from the column, RNA was treated with RNase-free DNase I (Qiagen). The purified, DNA-free RNA was converted to complementary DNA (cDNA) using SuperScript III reverse transcriptase (Invitrogen). Template cDNA and gene-specific primers (for rat CCN3, 5Ј-TCATTGGAA-CCTGTACCTGCCACT-3Ј [forward] and 5Ј-TCCCTGGGC-ACCTGTTACATTTCT-3Ј [reverse]) were added to Fast SYBR Green Master Mix (Applied Biosystems) and messenger RNA (mRNA) expression was quantified using the StepOnePlus Real-Time PCR system (Applied Biosystems). GAPDH and ␤-actin were used to normalize the mRNA expression. Melting curves were analyzed to verify the specificity of the RT-PCR and the absence of primer-dimer formation. Each sample was analyzed in duplicate, and each analysis included a template-free control. All of the primers were synthesized by Integrated DNA Technologies.
Immunofluorescence microscopy. Cells were plated in 96-well flat-bottomed plates (4 ϫ 10 3 cells/well) and were treated for 6-24 hours with TGF␤. After incubation, cells were fixed with 4% paraformaldehyde, permeabilized for 10 minutes with 0.2% Triton X-100 in PBS, blocked by overnight incubation at 4°C with PBS containing 5% FBS, and incubated with antibodies against CCN3 (1:200 dilution). As a negative control, cells were reacted with isotype IgG under similar conditions. After washing, the cells were incubated with Alexa Fluor 488-conjugated anti-rabbit secondary antibody (Invitrogen) at a dilution of 1:200 for 45 minutes at room temperature. Cells were imaged using a laser scanning confocal microscope (Olympus FluoView).
Western blotting. Cells were placed on ice immediately following treatment and washed with ice-cold Hanks' balanced salt solution. All of the wash buffers and final resuspension buffer included a 1ϫ protease inhibitor cocktail (Roche), NaF (5 mM), and Na 3 VO 4 (200 M). Total cell proteins were resolved on 8-12% sodium dodecyl sulfate-polyacrylamide gels and transferred by electroblotting to PVDF membranes (Bio-Rad). The membranes were blocked with 5% nonfat dry milk in TBST (50 mM Tris, pH 7.6, 150 mM NaCl, 0.1% Tween 20) and incubated overnight at 4°C in 3% nonfat dry milk in TBST with the anti-CCN3 (1:600 dilution) or anti-␤-tubulin (1:2,000 dilution) antibody (both from DSHB) or anti-GAPDH (1:2,000 dilution; Cell Signaling Technology). Immunolabeling was detected using enhanced chemiluminescence reagent (Amersham Biosciences).
Transfections and dual-luciferase assay. One day before transfection, cells were transferred to 24-well plates at a density of 4 ϫ 10 4 cells/well. To measure the effect of TGF␤, cells were transfected with 500 ng of CCN3 reporter plasmids with 500 ng of the pRL-TK plasmid. In some wells, cells were treated with the inhibitors SB203580 (10 M), SB202190 (10 M), or PD98059 (10 M) (all from Calbiochem). To investigate the effect of Smad3 or AP-1 on CCN3 promoter activity, cells were cotransfected with A-Fos (100-300 ng), TAM67 (100-300 ng), DN-Smad3 (100-300 ng), Smad3 (100-300 ng), or backbone vector with 400 ng of CCN3 reporter and 300 ng of pRL-TK plasmid in the presence or absence of TGF␤ (10 ng/ml). To investigate the effects of p38 and ERK signaling, cells were transfected with 100-300 ng of dominant-negative p38␣, ␤2, ␥, or ␦ isoforms or 100-300 ng of DN-ERK-1 or ERK-2. For each transfection, plasmids were premixed with the transfection reagent (Lipofectamine 2000; Invitrogen). The next day, the cells were harvested and a dual-luciferase reporter assay system (Promega) was used for sequential measurements of firefly and Renilla luciferase activities. Quantification of luciferase activities and calculation of relative ratios were carried out using a luminometer (TD-20/20; Turner Designs). At least 3 independent transfections were performed, and all analyses were carried out in triplicate.
Lentiviral particle production and viral transduction. Two days before transfection, HEK 293T cells were seeded in 10-cm plates (1.3 ϫ 10 6 cells/plate) in DMEM with 10% heat-inactivated FBS. Cells were transfected with 2.5 g of psiLv-H1-EGFP, pLVTHM-LacZ, and shSmad3 plasmids, along with 1.875 g of psPAX-2 and 0.625 g of pMD2.G. After 16 hours, the transfection medium was removed and replaced with DMEM containing 5% heat-inactivated FBS and penicillin/streptomycin. Lentiviral particles were harvested at 48 and 60 hours posttransfection. One day before transduction, nucleus pulposus cells were plated in DMEM with 5% heatinactivated FBS. Cells (in 10-cm plates) were transduced with 5 ml of conditioned medium containing viral particles along with 6 g/ml of Polybrene. After 24 hours, the conditioned medium was removed and replaced with DMEM containing 5% heat-inactivated FBS with 5 g/ml of doxycycline. Cells were harvested for protein extraction 5 days after viral transduction.
MTT assay. Cell proliferation was measured by MTT assay. After treatment for 24 or 72 hours, MTT diluted in serum-free DMEM was added to the culture medium to a final concentration of 0.5 mg/ml. At the end of the incubation period (2 hours at 37°C), the medium was removed, and the precipitated formazan crystals were solubilized in DMSO. Product formation was measured by reading the absorbance at 560 nm using a microplate reader (SpectraFluor Plus; Tecan).
Cell cycle analysis. Following treatment, single-cell suspensions were prepared from cell cultures and fixed for 1 hour in ice-cold 70% ethanol. Cells were washed and resuspended in PBS with 5% FBS. Cells were incubated with 50 M propidium iodide for 30 minutes at 37°C. Cell cycle analysis was conducted using a Coulter Epics XL-MCL system with XL System II software.
Statistical analysis. All measurements were performed in triplicate. Results are presented as the mean Ϯ SEM. Differences between groups were analyzed by Student's t-test. P values less than 0.05 were considered significant.
RESULTS

Expression of CCN3 in the intervertebral disc.
Sagittal sections of neonatal ( Figure 1A ) and skeletally mature ( Figure 1B ) rat intervertebral discs were stained with an antibody to CCN3 or were counterstained with hematoxylin and eosin and with Alcian blue (Figures 1C and D) . (Negative controls were also prepared, and the results are available upon request from the author.) As indicated in Figures 1A and B, CCN3 was expressed by cells of the nucleus pulposus, anulus fibrosus, and cartilaginous end plate. In the embryonic nucleus pulposus, staining was localized to the cytosol as well as to the pericellular matrix. In contrast, at this early stage in the anulus fibrosus, staining was primarily cellular. In skeletally mature animals, both discal tissues showed cellular as well as pericellular staining. CCN3 expression in the embryonic discs was more prominent than that in discs from skeletally mature animals.
Expression of CCN3 in native tissues and cultured cells was studied using Western blot analysis. Both nucleus pulposus and anulus fibrosus tissues expressed a 54-kd band, representing the full-length secreted CCN3 ( Figure 1E ), while a prominent 48-kd band, representing intracellular CCN3, was expressed in cultured nucleus pulposus and anulus fibrosus cells ( Figure 1F ). Western blot analysis of conditioned media from nucleus pulposus cells showed that full-length CCN3 was secreted into the media ( Figure 1H ).
TGF␤-induced decrease in CCN3 gene expression in nucleus pulposus cells. To explore the premise that TGF␤ regulates CCN3 expression, nucleus pulposus cells were treated with TGF␤, and expression of CCN3 was analyzed by real-time RT-PCR. Figure 1G shows that treatment with TGF␤ for 4, 8, and 24 hours significantly decreased CCN3 mRNA levels in nucleus pulposus cells. Western blot analysis indicated a similar decline in CCN3 protein expression with TGF␤ treatment ( Figure 1H ). TGF␤ treatment also decreased the levels of secreted CCN3 ( Figure 1H ), although at 24 hours, secreted levels had returned to baseline levels. Densitometric analysis of Western blots from 3 independent experiments was performed and showed significant suppression of CCN3 protein levels by TGF␤ ( Figure  1I ). Likewise, immunofluorescence microscopy of TGF␤-treated nucleus pulposus cells showed that treatment caused a strong decrease in CCN3 expression ( Figure 1J ).
To investigate whether TGF␤ regulates CCN3 promoter activity, we transfected nucleus pulposus cells with a human CCN3 promoter construct encompassing amino acid positions -1257 to ϩ317 ( Figure 1K ) and measured promoter activity following treatment of cells with TGF␤. CCN3 promoter activity was significantly decreased with TGF␤ treatment (Figure 2A ). To confirm the involvement of TGF␤ signaling, cells were cotransfected with increasing doses of DN-ALK-5, the primary TGF␤ type I receptor in nucleus pulposus cells. Figure 2B shows that coexpression of the DN-ALK-5 blocks suppression of CCN3 promoter activity by TGF␤. CCN3 promoter activity also decreased when cells were cotransfected with constitutively activated CA-ALK-5 in the absence of TGF␤ ( Figure 2C ), suggesting a role for TGF␤ in the regulation of CCN3 expression in nucleus pulposus cells.
Independence of TGF␤-induced CCN3 suppression on Smad and AP-1 signaling. To elucidate the mechanism of CCN3 suppression by TGF␤, we first investigated the involvement of the Smad signaling pathway. Nucleus pulposus cells were cotransfected with DN-Smad3 ( Figure 2D ) or small interfering RNA (siRNA) against Smad3 (data available upon request from the author), and then treated with TGF␤. Figure  2D shows that blocking Smad3 function had no effect on TGF␤ suppression of CCN3 promoter activity. Next, we examined another important mediator of TGF␤ action, the AP-1 pathway, which we previously showed to be induced by TGF␤ in the nucleus pulposus (22) . Cells were cotransfected with dominant-negative forms of the Fos (A-Fos) and Jun (TAM67) subunits of AP-1, which inhibit the transcriptional activity of endogenous AP-1. Figures 2E and F indicate that coexpression of either of the DN-AP-1 subunits had no effect on TGF␤-dependent actions on the CCN3 promoter activity. Control experiments were performed using Smadresponsive 3TP-Lux and AP-1-responsive reporters to validate the inhibitory function of DN-Smad3 ( Figure  2G ), TAM67, and A-Fos plasmids ( Figure 2H) .
Role of MAPK signaling in TGF␤ suppression of CCN3. We next investigated the involvement of the MAPK signaling pathway in TGF␤-mediated suppression of CCN3 promoter activity. Nucleus pulposus cells were treated with a p38 inhibitor (SB203580 or SB202190) or an ERK inhibitor (PD98059) or their combination in the presence of TGF␤. As shown in Figure 3A , treatment with the individual p38 and ERK inhibitors partially counteracted the suppressive effects of TGF␤ on CCN3 promoter activity. The combination of p38 and ERK inhibitors rescued CCN3 promoter activity almost to basal levels ( Figure 3A) . As a control, cells were treated with p38 and ERK inhibitors without TGF␤, which did not cause a significant change in CCN3 promoter activity (data available upon request from the author). Real-time quantitative PCR analysis of cells treated with the combination of MAPK inhibitors in the presence of TGF␤ confirmed this regulation at the mRNA level ( Figure 3B ). We then cotransfected nucleus pulposus cells with plasmids encoding DN-p38 isoforms ␣, ␤, ␥, or ␦ to examine which isoform is important for mediating TGF␤ suppression of CCN3. Figures 3C and D show that, individually, neither of the dominant-negative isoforms of p38 blocked the suppressive effects of TGF␤ on CCN3 promoter activity (results not shown for DN-p38␣ and DN-p38␥). Similarly, cotransfections with DN-ERK-1 and DN-ERK-2 also showed little effect on CCN3 promoter activity ( Figures  3E and F) .
Positive regulation of CCN3 expression by Smad3. To further determine if Smad3 exerts an effect independent of TGF␤ signaling on CCN3 promoter activity, we overexpressed Smad3 in nucleus pulposus cells in the absence of exogenous TGF␤. Surprisingly, cotransfection with Smad3 resulted in an almost 7-fold increase in CCN3 promoter activity ( Figure 4A ). Figure  4B shows that overexpression of Smad3 in the presence of TGF␤ rescued the suppression of CCN3 promoter activity by the growth factor. We suppressed Smad3 expression in nucleus pulposus cells by transduction with lentivirus expressing Smad3 short hairpin RNA (shRNA). Figure 4C shows that there was a significant decrease in Smad3 expression in nucleus pulposus cells and that shRNA-mediated suppression was specific to Smad3. CCN3 expression was reduced in the shSmad3-transduced cells compared to nontransduced cells or cells transduced with control shRNA ( Figure 4C) . green fluorescence protein image to the transmittedlight image showed that most of the cells were transduced with the lentivirus (Figures 4D and E) . To confirm these results, sections of intervertebral disc from wild-type mice ( Figure 4F ) and Smad3-null mice ( Figure 4G ) were stained with a CCN3 antibody. The Smad3-null mouse disc showed less CCN3 expression than the wild-type disc ( Figure 4G ). Similarly, when Smad3 was overexpressed in embryonic fibroblasts derived from Smad3-null mice, a significant increase in CCN3 promoter activity was seen ( Figure  4H ). Last, treatment of Smad3-null mouse embryonic fibroblasts with TGF␤ decreased CCN3 expression (Figure 4I) .
CCN3-modulated proliferation of nucleus pulposus cells. To delineate the effect of CCN3 on nucleus pulposus cell proliferation, we treated cells with an increasing dose of recombinant CCN3 (10-500 ng/ml) for 24 or 72 hours. Figures 5A and B show phasecontrast microscopy images of cells treated with 100 ng/ml of CCN3 for 24 hours ( Figure 5A ) compared with control ( Figure 5B ). There was no appreciable differ- ence in cellular morphology between the treated and untreated groups, although cell density appeared lower in the treated group. MTT assay showed that cell proliferation decreased with increasing doses of CCN3 at 24 and 72 hours (Figures 5C and D) . To examine whether the effect on proliferation was due to modulation of the cell cycle, we treated cells with 100 ng/ml of CCN3, and cell cycle analysis was performed using fluorescence-activated cell sorting (FACS). The results from 4 independent experiments showed that CCN3 had no significant effect on the cell-cycle status of nucleus pulposus cells, with a mean Ϯ SEM of 81.34 Ϯ 4.7% of control cells in G 0 /G 1 phase, 5.37 Ϯ 2% in S phase, and 12.12 Ϯ 5.91% in G 2 /M phase, and with 76.9 Ϯ 8.2% of CCN3-treated cells in G 0 /G 1 phase, 8.02 Ϯ 3.5% in S phase, and 14.83 Ϯ 5.2% in G 2 /M phase. To examine the effect of CCN3 on TGF␤-dependent cell proliferation, we treated the cells with TGF␤ or with TGF␤ together with CCN3 for 72 hours. Figure 5E shows that TGF␤ treatment resulted in a small increase in cell proliferation, but when combined with CCN3, there was no significant difference in cell proliferation.
CCN3-modulated expression of critical extracellular matrix genes in the nucleus pulposus. Finally, we examined the effect of CCN3 treatment on the expression of critical extracellular matrix genes in the nucleus pulposus cells. As shown in Figures 6A-C, treatment with CCN3 decreased the expression of versican, aggrecan, and type I collagen after 24 hours. In addition, we treated cells with recombinant CCN2 and measured the expression of the same matrix genes (Figures 6A-C) . In contrast to CCN3, CCN2 strongly induced aggrecan mRNA expression at all time points examined. To explore the possibility that these CCN proteins could regulate each other, as has been speculated in relation to other cell types (23, 24) , we treated the cells with either CCN2 or CCN3 and measured the expression of the corresponding CCN. CCN3 treatment decreased CCN2 expression by nucleus pulposus cells ( Figure 6D ), while CCN2 treatment decreased CCN3 expression transiently at 4 and 8 hours, but showed no effect at 24 hours ( Figure 6E ).
DISCUSSION
The experiments in this investigation demonstrated for the first time that CCN3 was expressed in nucleus pulposus cells of the intervertebral disc and that its basal expression was regulated by TGF␤. Growth factor suppression of CCN3 transcription was partially mediated through p38 and ERK signaling pathways, independent of Smad and AP-1 signaling. When treated with CCN3, nucleus pulposus cells elicited a dosedependent decrease in cell number and lowered expression of versican, aggrecan, type I collagen, and CCN2. These studies also revealed that TGF␤ signaling induces CCN3 promoter activity through Smad3 while also enhancing CCN3 repression via MAPK signaling. We propose that the repressive activity of MAPK signaling and as-yet-unknown transcription factors exceeds the stimulatory response generated by the Smads. To our knowledge, this is the first study in which Smad signaling and TGF␤ signaling were decoupled, thereby promoting opposing effects on target gene transcription. We suggest that during disc degeneration, an increase in TGF␤ activity and the corresponding changes in CCN3 and CCN2 expression, as we reported previously, could trigger a reparative response that may influence the remodeling response of the extracellular matrix and the proliferative status of the cells (22) .
The expression and localization of CCN3 in the intervertebral disc was age dependent. In the embryonic disc, there was robust expression in both anulus fibrosus and nucleus pulposus cells. In contrast, in the adult disc, there was a lower level of CCN3 protein expression in both tissue types. Immunofluorescence analysis of the mature disc indicated that staining was both cellular and pericellular, suggesting that the protein was being secreted and possibly trapped in the pericellular matrix. This notion was substantiated by Western blot analysis of adult discal tissues, where a prominent 54-kd band corresponding to the full-length secreted CCN3 protein was seen (25) . From this perspective, CCN3, like CCN2, must be considered to be a matrix constituent of the disc. That intracellular levels of CCN3 are regulated by TGF␤ was evident from studies of cultured nucleus pulposus cells. Treatment with TGF␤ suppressed the expression of CCN3 mRNA as well as protein. We confirmed that TGF␤ suppressed CCN3 activity by using a dominantnegative TGF␤ receptor type I/activin receptor-like kinase 5 (ALK-5) construct. When cells were transfected with this construct in the presence of TGF␤, there was a dose-dependent restoration of CCN3 promoter activity. Likewise, in the absence of the growth factor, transfection with a constitutively active ALK-5 construct decreased CCN3 promoter activity. Results of these experiments suggest that TGF␤ is concerned with the basal regulation of CCN3 in nucleus pulposus cells of the intervertebral disc.
We examined the mechanism by which TGF␤ suppresses CCN3 expression by examining both Smad and non-Smad transduction pathways. With respect to MAPK and AP-1, Lafont et al (26) have previously shown that in adrenocortical cells, CCN3 suppression was dependent on AP-1 signaling. To ascertain whether a similar regulation was functional in the nucleus pulposus, we transfected cells with dominant-negative Fos and Jun subunits of AP-1. Surprisingly, neither of these proteins influenced growth factor-dependent CCN3 promoter activity. In a parallel study, we found that treatment with p38 and ERK inhibitors partially blocked the TGF␤-mediated suppression of CCN3 promoter activity as well as the mRNA expression.
Thus, from a regulatory perspective, it would appear that in discal tissues, regulation of CCN3 expression by TGF␤ is unique and more complex than was originally thought. Indeed, trying to delineate which MAPK isoforms are most likely to be required for suppression is not obvious. Transfection with individual dominant-negative isoforms of p38 (p38␣, p38␤, p38␥, and p38␦) or ERK (ERK-1 and ERK-2) showed no effect on CCN3 promoter activity. One interpretation of these results is that more than one isoform is required for CCN3 promoter suppression by TGF␤ or, possibly, that there is some isoform redundancy. The importance of these and other noncanonical signaling pathways in mediating TGF␤ suppression of CCN3 is under active investigation.
To examine the involvement of the Smad signaling pathway, the more conventional transducer of TGF␤ signaling, we cotransfected cells with DN-Smad3 and Smad3 siRNA in the presence of TGF␤. The observation that neither strategy rescued CCN3 promoter activity suggested that Smad3 is not involved in the suppression of CCN3. This result was not surprising, since earlier studies indicated that in both mesangial and adrenocortical cells, TGF␤ suppression of CCN3 is independent of Smad3 (23, 26) . Interestingly, in the course of the current investigation, we observed that overexpression of Smad3 caused a dose-dependent activation of CCN3 promoter activity. This result was further confirmed using Smad3-null mouse embryonic fibroblasts. When cells were transfected with increasing doses of Smad3, there was a dose-dependent increase in CCN3 promoter activity. In terms of disc cells, we observed a decrease in CCN3 protein levels in both the nucleus pulposus and anulus fibrosus of Smad3-null mice as compared to their wild-type littermates. We confirmed this Smad3-dependent regulation in nucleus pulposus cells by suppressing Smad3 levels using lentiviral transduction.
Thus, it is evident that Smad3 is more concerned with maintenance of basal CCN3 expression in nucleus pulposus cells than its control when high levels of TGF␤ are present. Since the net effect of TGF␤ treatment is suppression of CCN3 expression, one obvious interpretation of this result is that the stimulatory effect of Smad3 must be offset by inhibitory activities of a TGF␤-induced repressor molecule(s). It is possible that this could be achieved by limiting the binding of Smad3 to its response element by activation of the noncanonical pathway. Based on these observations, we propose a model of CCN3 regulation by TGF␤ in nucleus pulposus cells that involves both canonical (Smad) and noncanonical (MAPK) signaling pathways ( Figure 6F ). Accordingly, TGF␤ signaling through ALK-5 induces both activators and repressors of CCN3: the activating arm of this pathway is mediated by Smad3, while the repressive arm is through MAPK signaling. Activation of the latter arm and the generation of as-yet-unknown repressors could possibly override the stimulation generated by the Smads by limiting their access to the promoter.
In terms of a physiologic role of CCN3, we observed that it influenced matrix gene expression as well as the proliferative response of nucleus pulposus cells. When treated with CCN3, there was a dosedependent decrease in cell number, similar to what has been observed in other cell types (13) (14) (15) (16) (17) . FACS analysis indicated that the change in proliferation was not caused by an arrest of cell cycle progression in the G 2 /M phase, as has been reported for glioma cells (27) . As suggested by Fu et al and Sakamoto et al (15) (16) (17) , CCN3 may exert its antiproliferative activity by its association with notch and Notch ligands and the connexin 43 signaling pathways (15) (16) (17) . Consistent with previous reports, we also found that TGF␤ caused an increase in nucleus pulposus cell proliferation (28, 29) . This effect was not blocked with addition of CCN3, indicating that TGF␤ overrides the antiproliferative function of CCN3.
With regard to its effects on matrix genes, CCN3 caused alterations in the expression of aggrecan, versican, and type I collagen, matrix genes that are known to be expressed by cells of the nucleus pulposus. It also caused a similar decrease in the expression of CCN2, a CCN family member that we have shown to be upregulated by TGF␤ in the nucleus pulposus and to promote aggrecan synthesis (22, 30) . The opposite effects of the two CCN proteins on aggrecan expression are noteworthy: CCN3 decreases, while CCN2 promotes, aggrecan expression. The opposing effects of TGF␤ on CCN2 and CCN3 expression and the suppression of CCN2 by CCN3 lend considerable strength to the notion that these molecules may form a regulatory triad (23, 24) . Since, during disc degeneration, there is a trend toward increased TGF␤ expression, the decrease in CCN3 expression and a concomitant increase in CCN2 may 3030 TRAN ET AL promote a reparative response, enhancing matrix synthesis and promoting changes in cell number-events that are common in all tissues undergoing fibrotic degeneration. Whether the effects of TGF␤ on CCN2 and CCN3 expression vary according to degenerative stage is not known. However, it would not be unreasonable to assume that each of the components of the regulatory circuit provides novel pharmacologic targets for the treatment of degenerative disc disease.
